The pairing of Merck's blockbuster immunotherapy Keytruda and Eisai's Lenvima has previously failed in studies evaluating it in patients with types of head-and-neck cancer, skin cancer and colon cancer as well. In both the lung cancer studies, LEAP-006 and LEAP-008, the combination did not improve overall survival in patients, which was one of the two main goals for both.
Eisai Co., Ltd. (OTCMKTS:ESALY – Get Free Report) shares crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $61.51 and traded as low as $61.00. Eisai shares last traded at $61.51, with a volume of 331,800 shares changing hands. Analyst Upgrades and Downgrades […]